Literature DB >> 11261328

The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia.

R Jantunen1, E Juvonen, E Ikkala, K Oksanen, P Anttila, T Ruutu.   

Abstract

The impact of the cardiovascular risk factors smoking, hypertension, hypercholesterolemia, and diabetes mellitus on the risk of thrombotic complications was evaluated retrospectively in 132 patients with essential thrombocythemia (ET). The median age at diagnosis was 51 years, and the median follow-up time was 65 months. Sixty-three out of 132 patients (48%) had one or more vascular risk factors, whereas 69 patients (52%) had no risk factors. Thirty-two patients were smokers, 27 had hypertension, 21 hypercholesterolemia, and four diabetes mellitus. During the follow-up, 53 patients (40%) had 98 arterial thrombotic events, half of which were disturbances of cerebral circulation. Fifteen patients (11%) experienced 27 venous thrombotic events. The presence of one or more vascular risk factors increased the risk of arterial thrombotic complications. Of the patients, 52% with one or more vascular risk factors and 29% of those without any risk factors had arterial thrombosis (P = 0.01). In multivariate analysis the only independent risk factor was smoking (P = 0.01). Male gender increased the risk of arterial thrombosis significantly. Thirty-six out of 62 men (58%) but only 17 out of 70 women (24%) had an arterial complication (P < 0.001). Smoking had a strong predictive value for the development of arterial complications in women but not in men. Among women 9/15 (60%) of the smokers and 12/82 (15%) of the non-smokers experienced arterial thrombosis (P = 0.002), whereas among men no difference between smokers and non-smokers could be found. According to the present findings, the male gender should be regarded as a risk factor when deciding about the indication for treatment. Smoking should be discouraged especially among women with ET.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11261328     DOI: 10.1007/s002770000244

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  7 in total

1.  Neurological disorders in essential thrombocythemia.

Authors:  Segolene Billot; Eirini G Kouroupi; Johan Le Guilloux; Bruno Cassinat; Caroline Jardin; Thierry Laperche; Pierre Fenaux; Antoine F Carpentier; Jean-Jacques Kiladjian
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

Review 2.  Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Authors:  L Falchi; H M Kantarjian; S Verstovsek
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

3.  Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms.

Authors:  Loula Papageorgiou; Ismail Elalamy; Patrick Vandreden; Grigoris T Gerotziafas
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

4.  Thrombotic complications in childhood-onset idiopathic membranous nephropathy.

Authors:  Chrystal U Louis; Bruce Z Morgenstern; Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2003-10-30       Impact factor: 3.714

5.  Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.

Authors:  Jonathan S Bleeker; William J Hogan
Journal:  Thrombosis       Date:  2011-06-08

Review 6.  Essential thrombocythemia.

Authors:  Jean B Brière
Journal:  Orphanet J Rare Dis       Date:  2007-01-08       Impact factor: 4.123

7.  Aortic valve replacement in a young patient with essential thrombocytosis.

Authors:  Kashif Ahmed; Hunaid A Vohra; Alison Milne; Stephen M Langley
Journal:  J Cardiothorac Surg       Date:  2008-01-30       Impact factor: 1.637

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.